Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs ZYME: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ZYME Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)
ZYME Overall Winner
6-Pillar Tally: NUVB 0 – 6 ZYME
Matrix Metrics: NUVB 2 – 8 ZYME
As of Nov 20, 2026, Zymeworks Inc. (ZYME) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas ZYME carries 59.5/100 (HOLD) at $26.14 (55.0x Forward P/E, 22.6% operating margin).
- Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ZYME 59.5/100 HOLD), ZYME captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.6% vs. -61.2% operating margin) and revenue trajectory (+828.7% vs. +242.6% YoY).
- Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ZYME trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NUVB vs ZYME
NUVB
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
ZYME
Head-to-Head Winner
Zymeworks Inc.
$26.14
-2.68% 1D
Market Cap
$1.9B
TTM Revenue
$266M
Forward P/E
55.0x
Beta / 30D Vol
0.87β · 56% Vol
Unified Composite Score
59.5
HOLD
Tech 60.0
Fund 59.0
Flow 67.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (NUVB 0 – 6 ZYME)
1. Valuation Multiples
ZYME
Forward P/E
N/M
55.0x
Trailing P/E
N/M
50.7x
PEG Ratio
N/M
N/M
EV / Revenue
7.4x
6.8x
2. Growth & Scale
ZYME
Revenue Growth (YoY)
+242.6%
+828.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$202M
$266M
Market Cap
$1.3B
$1.9B
3. Profitability & Quality
ZYME
Gross Margin
85.8%
51.7%
Operating Margin
-61.2%
22.6%
Net Profit Margin
-67.4%
16.3%
Return on Equity (ROE)
-49.1%
15.0%
4. Balance Sheet & Cash Flow
ZYME
Cash Generation (TTM)
-$108M
-$113M
Cash Flow Margin
-53.6%
-42.5%
Net Cash / Leverage
$146M Net Debt (1.32x D/E)
$47M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ZYME
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
65.2% (26th %ile)
350.4% (45th %ile)
Put/Call OI Skew
0.24x (Call-Skewed)
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
ZYME
OpEx & R&D Intensity
N/A
29.1% of Rev ($77M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NUVB (2) vs ZYME (8)| Institutional Metric | NUVB | ZYME | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.3B | $1.9B | ZYME | |
| Trailing P/E Ratio | N/M | 50.7x | ZYME | |
| Forward P/E Ratio | N/M | 55.0x | ZYME | |
| Revenue Growth (YoY) | +242.6% | +828.7% | ZYME | |
| Operating Margin (TTM) | -61.2% | 22.6% | ZYME | |
| Net Profit Margin | -67.4% | 16.3% | ZYME | |
| Return on Equity (ROE) | -49.1% | 15.0% | ZYME | |
| 52-Week Range Position | 2% ($4–$10) | 44% ($22–$32) | ZYME | |
| Beta / 30D Volatility | 1.52β · 55% Vol | 0.87β · 56% Vol | NUVB | |
| Unified Institutional Score | 61.0 / 100 (BUY) | 59.5 / 100 (HOLD) | NUVB | |
| Trailing 12M Revenue (USD) | $202M | $266M | Scale | |
| Gross Profit Margin (TTM) | 85.8% | 51.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.4x EV/Rev | N/M PEG · 6.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$108M ($146M Net Debt (1.32x D/E)) | -$113M ($47M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ZYME +11.06 pp
3M Horizon
ZYME +34.65 pp
6M Horizon
ZYME +21.56 pp
1Y Horizon
ZYME +62.51 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | ZYME Revenue | NUVB Op. Margin | ZYME Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $40M | N/A | -481.3% | ZYME |
| FY2021 | N/A | $30M | N/A | -808.2% | ZYME |
| FY2022 | N/A | $410M | N/A | 31.6% | ZYME |
| FY2023 | N/A | $80M | N/A | -181.6% | ZYME |
| FY2024 | $10M | $80M | -7527.3% | -179.7% | ZYME |
| FY2025 | $60M | $110M | -338.7% | -87.3% | ZYME |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ZYME
CONSOLIDATION
Current IV
350.4%
IV Percentile
45th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ZYME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ZYME Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
OpEx & R&D Reinvestment
29.1% of Rev ($77M)
90D Engineering Disclosures
0 Published
Investor FAQ NUVB vs ZYME Key Questions & Quantitative Answers
As of Nov 20, 2026, Zymeworks Inc. (ZYME) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas ZYME carries 59.5/100 (HOLD) at $26.14 (55.0x Forward P/E, 22.6% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ZYME 59.5/100 HOLD), ZYME captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (22.6% vs. -61.2% operating margin) and revenue trajectory (+828.7% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile ZYME trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZYME leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with ZYME at +828.7% YoY revenue growth and +0.0% YoY earnings growth on $266M TTM revenue (51.7% gross margin, 22.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), NUVB cumulative revenue shifted +500.0% while ZYME shifted +175.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus 29.1% of Rev ($77M) (0 disclosures) for ZYME.
ZYME screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas ZYME trades at 55.0x Forward P/E, 50.7x Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-42.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus ZYME (15.0% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, ZYME carries 350.4% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ZYME vs NUVB · Reverse Pair
NUVB vs LYEL
· Sector Peer
NUVB vs TSHA
· Sector Peer
NUVB vs STOK
· Sector Peer
ZYME vs RCUS
· Sector Peer
ZYME vs XNCR
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem